Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ$0.3036
Market Cap
$3.42M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
546 of 924
Rank in Industry
318 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
CYCC Insider Trading Activity
CYCC Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced …
Insider Activity of Cyclacel Pharmaceuticals, Inc.
Over the last 12 months, insiders at Cyclacel Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Cyclacel Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Cyclacel Pharmaceuticals, Inc. have bought $26,374 and sold $5.51M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 6,070 shares for transaction amount of $20,122 was made by Rombotis Spiro George (President and CEO) on 2023‑12‑21.
List of Insider Buy and Sell Transactions, Cyclacel Pharmaceuticals, Inc.
| 2025-02-26 | Sale | Lazar David E. | Interim CEO | 194.63M – | $0.03 | $5.51M | +0.28% | |
| 2023-12-21 | Rombotis Spiro George | President and CEO | 6,070 0.6595% | $3.31 | $20,122 | -53.61% | ||
| 2023-12-21 | McBarron Paul | See Remarks | 1,886 0.2049% | $3.31 | $6,252 | -53.61% | ||
| 2017-02-23 | TANG KEVIN C | 10 percent owner | 134,200 3.3648% | $4.34 | $582,079 | -53.33% | ||
| 2014-11-20 | BARKER SAM L | director | 3,100 0.0137% | $3.00 | $9,300 | -76.12% | ||
| 2013-05-21 | Rombotis Spiro George | President and CEO | 200,000 1.4075% | $3.00 | $600,000 | +16.94% | ||
| 2013-05-21 | McBarron Paul | See Remarks | 12,948 0.092% | $3.03 | $39,213 | +16.94% | ||
| 2013-05-21 | Sems Lloyd | director | 33,333 0.2346% | $3.00 | $99,999 | +16.94% | ||
| 2011-12-23 | Rombotis Spiro George | President and CEO | 15,902 0.0288% | $0.49 | $7,871 | +17.14% | ||
| 2011-09-23 | Sale | MARXE AUSTIN W & GREENHOUSE DAVID M | 10 percent owner | 650,000 1.2397% | $0.51 | $332,930 | +12.00% | |
| 2011-09-23 | Rombotis Spiro George | President and CEO | 24,100 0.0453% | $0.51 | $12,171 | +12.00% | ||
| 2011-09-23 | McBarron Paul | See Remarks | 12,000 0.0223% | $0.50 | $6,000 | +12.00% | ||
| 2011-09-22 | Sale | MARXE AUSTIN W & GREENHOUSE DAVID M | 10 percent owner | 500,000 1.0235% | $0.60 | $302,350 | +1.56% | |
| 2011-09-22 | Rombotis Spiro George | President and CEO | 5,000 0.01% | $0.59 | $2,965 | +1.56% | ||
| 2011-09-13 | Rombotis Spiro George | President and CEO | 12,400 – | $0.75 | $9,343 | -21.68% | ||
| 2011-08-22 | Rombotis Spiro George | President and CEO | 9,232 0.0171% | $0.73 | $6,721 | -21.92% | ||
| 2011-05-13 | Sale | MARXE AUSTIN W & GREENHOUSE DAVID M | 10 percent owner | 150,000 0.3324% | $1.75 | $263,200 | -61.18% | |
| 2010-11-30 | Sale | MARXE AUSTIN W & GREENHOUSE DAVID M | 10 percent owner | 142,000 0.3167% | $1.90 | $269,871 | -29.51% | |
| 2010-11-26 | Sale | MARXE AUSTIN W & GREENHOUSE DAVID M | 10 percent owner | 58,000 0.1253% | $1.90 | $110,310 | -31.75% | |
| 2010-10-08 | Sale | MARXE AUSTIN W & GREENHOUSE DAVID M | 10 percent owner | 183,982 0.3957% | $1.67 | $307,728 | -17.07% |
Total: 183
*Gray background shows transactions not older than one year
*Some uncertain data for Preferred Stock share type transactions are shown in italics; for actual data please follow the link
Insider Historical Profitability
<0.0001%
| MARXE AUSTIN W & GREENHOUSE DAVID M | 10 percent owner | 2806900 24.9367% | $852,174.84 | 32 | 10 | |
| MORGAN STANLEY | 10 percent owner | 2276852 20.2277% | $691,252.27 | 32 | 34 | |
| LAZARUS STEVEN | 10 percent owner | 2054271 18.2503% | $623,676.68 | 1 | 0 | |
| CRANDELL KEITH | 10 percent owner | 2054271 18.2503% | $623,676.68 | 1 | 0 | |
| NELSEN ROBERT | director, 10 percent owner | 2054271 18.2503% | $623,676.68 | 1 | 0 |
Historical Insider Profitability vs. Competitors
$18,881,323 | 88 | -48.96% | $3.75M | |
$296,936 | 37 | -18.12% | $4.42M | |
$1,138,733 | 28 | -4.94% | $2.7M | |
$1,616,354 | 20 | -12.22% | $3.22M | |
$960,082 | 17 | -6.29% | $3.61M |
CYCC Institutional Investors: Active Positions
| Increased Positions | 10 | +100% | 506,780 | +250.43% |
| Decreased Positions | <1 | -10% | 166 | -0.08% |
| New Positions | 5 | New | 34,717 | New |
| Sold Out Positions | <1 | Sold Out | 166 | Sold Out |
| Total Postitions | 19 | +90% | 708,979 | +250.35% |
CYCC Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Armistice Capital, Llc | $193.00 | 5.28% | 580,461 | +435,461 | +300.32% | 2024-12-31 |
| Ubs Group Ag | $16.00 | 0.43% | 47,317 | +34,764 | +276.94% | 2024-12-31 |
| Two Sigma Securities, Llc | $9.00 | 0.26% | 28,580 | +28,580 | New | 2024-12-31 |
| Point72 Asset Management, L.P. | $5.00 | 0.14% | 15,333 | 0 | 0% | 2024-12-31 |
| Acadian Asset Management Llc | $5.00 | 0.13% | 14,285 | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $4.00 | 0.1% | 10,817 | +219 | +2.07% | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $2.00 | 0.05% | 5,593 | +1,583 | +39.48% | 2024-12-31 |
| Vsm Wealth Advisory, Llc | $2.00 | 0.05% | 4,935 | +4,935 | New | 2024-12-31 |
| Sbi Securities Co., Ltd. | $0 | 0.01% | 802 | +802 | New | 2024-12-31 |
| Archer Investment Corp | $0 | <0.01% | 200 | +200 | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.